# Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT04833114** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **GWT-TUD GmbH** · enrollment: 306 (actual)

## Conditions studied

- Relapsed Diffuse Large B-cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Mabthera
- **DRUG:** Ifosfamide
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04833114
- **Lead sponsor:** GWT-TUD GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-30
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2025-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04833114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04833114, "Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04833114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*